Real World Evidence (RWE) 101 – Compliance Maps
In the context of multi-country Real-World Evidence (RWE) studies, “Regulatory Compliance Maps” are essentially a detailed representation of the diverse regulatory requirements specific to each participating country.
RWE studies involve the analysis of data derived from a number of different sources outside of typical clinical trials, such as electronic health records (EHRs), medical claims and billing data, patient registries, and patient-generated data. Different countries have varied regulations regarding the use and sharing of such data, including the handling of patient privacy, data security, and informed consent among others.
To navigate through this complex landscape, regulatory compliance maps are created for several purposes:
[1] Understanding the Regulation: These maps help in identifying the specific regulatory requirements in each country. They define how to handle, process, store, and share patient data.
[2] Comparison: They also provide a comparative view of the regulatory landscape across different countries. This comparison allows companies to understand the relative complexity of conducting RWE studies in different regions.
[3] Planning: Based on these compliance maps, companies can strategise and design their RWE studies to ensure they meet all regulatory requirements. This might involve altering the study design or selecting specific data collection tools in different regions.
[4] Risk Mitigation: By understanding the specific regulations in each region, companies can take proactive steps to minimize risks associated with non-compliance, which might lead to legal repercussions or reputational damage.
[5] Collaboration: These maps also facilitate better communication and cooperation with local authorities, including IRBs/RECs, as they demonstrate the company’s understanding and respect for local regulations.
Creating and maintaining regulatory compliance maps can be a complex task due to the evolving nature of regulations, the diversity of data sources, and the need for expertise in different jurisdictional laws. However, it is an essential part of conducting efficient and ethical multi-country RWE studies.
Share this story...
Real World Evidence (RWE) 101 – ICH GCP (R3) – Real World Evidence Context
RWE 101 - ICH GCP (R3) - Real World Evidence Context Revision 2 of ICH GCP caused confusion to those of us who work with non-interventional studies. The glossary [...]
Real World Evidence (RWE) 101 – Non-Interventional Studies vs Market Health Research
RWE 101 - Non-Interventional Studies vs Market Health Research Key differences between a non-interventional study (NIS) and market health research include:1. Research Objective: NIS are conducted to examine real-world [...]
Real World Evidence (RWE) 101 – Real World Evidence (RWE) 101 – Audits vs Inspections
RWE 101 - Real World Evidence (RWE) 101 - Audits vs Inspections In the context of regulatory compliance for Real-World Evidence (RWE), both audits and inspections play crucial roles, [...]
Real World Evidence (RWE) 101 – A Career of Many Pathways
RWE 101 - A Career of Many Pathways Real-world evidence (RWE) refers to the information on health care that is derived from analysis of real-world data (RWD). RWE [...]
Real World Evidence (RWE) 101 – Evolution of Regulatory Affairs
RWE 101 - Evolution of Regulatory Affairs Real-world evidence (RWE) and real-world data (RWD) are increasingly influencing regulatory affairs in the biopharmaceutical and healthcare industry. This change has been [...]
Real World Evidence (RWE) 101 – Project Managers
RWE 101 - Project Managers Real-World Evidence (RWE) observational studies and clinical trials are both key elements of medical research, but they involve very different methodologies, aims, and requirements. [...]